Phase I and pharmacokinetic study of preirradiation chemotherapy with BCNU, cisplatin, etoposide, and accelerated radiation therapy in patients with high-grade glioma

Purpose: We conducted a Phase I study of bischloroethylnitrosourea (BCNU), cisplatin, and oral etoposide administered prior to and during accelerated hyperfractionated radiation therapy in newly diagnosed high-grade glioma. P harmacokinetic studies of oral etoposide were also done. Methods and Materials: Patients started chemotherapy after surgery but prio r to definitive radiation therapy (160 cGy twice daily x 15 days; 4800 cGy total). Initial chemotherapy consisted of BCNU 40 mg/m(2) days 1-3, cisplat in 30 mg/m(2) days 1-3 and 29-31, and etoposide 50 mg orally days 1-14 and 29-42, repeated in 8 weeks concurrent with radiation therapy. BCNU 200 mg/m (2) every 8 weeks x 4 cycles was given after radiation therapy. Results: Sixteen patients, 5 with grade 3 anaplastic astrocytoma and 11 wit h glioblastoma were studied. Grade 3-4 leukopenia (38%) and thrombocytopeni a (31%) were dose-limiting. Other toxicities were anorexia (81%), nausea (9 4%), emesis (56%), alopecia (88%), and ototoxicity (38%). The maximum toler ated dose was BCNU 40 mg/m2 days 1-3, cisplatin 20 mg/m(2) days 13 and 29-3 1, and oral etoposide 50 mg days 1-21 and 29-49 prior to radiation therapy and repeated in 8 weeks with the start of radiation therapy followed by BCN U 200 mg/m2 every 8 weeks for 4 cycles. Median time to progression and surv ival were 13 and 14 months respectively. Responses occurred in 2 of 9 (22%) patients with evaluable disease. In pharmacokinetic studies, all patients achieved plasma concentrations of >0.1 mu g/ml etoposide (the in vitro radi osensitizing threshold), following a 50 mg oral dose. The mean rt SD 2 hr a nd 6 hr plasma concentrations were 0.92 +/- 0.43 mu g/ml and 0.36 +/- 0.12 mu g/ml, respectively. Estimated duration of exposure to >0.1 mu g/ml etopo side was 10-17 hr. Conclusions: Preirradiation chemotherapy with BCNU, cisplatin, and oral eto poside with accelerated hyperfractionated radiation therapy in high-grade g liomas is feasible and merits further investigation. Sustained radiosensiti zing concentrations can be achieved with low oral doses of etoposide. (C) 1 998 Elsevier Science Inc.